Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22666432 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL20859716 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL22666168 | 0.78 | ALDH1A1 (0.37) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL17407677 | 0.76 | ALDH1A1 (0.36) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6139613 | 0.74 | ALDH1A1 (0.34) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6139399 | 0.74 | ALDH1A1 (0.34) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6138443 | 0.74 | ALDH1A1 (0.34) | NLRP3ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL6294142 | 0.73 | ALDH1A1 (0.33) | NLRP3ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL6294710 | 0.73 | ALDH1A1 (0.33) | NLRP3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL17080514 | 0.73 | ALDH1A1 (0.33) | NLRP3ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | claimed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | claimed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | claimed |
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | NLRP3 3484/4885ALDH1A1 575/4885LMNA 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.